Recent research involving ZSF1 rats, a model of metabolic syndrome and ventricular stiffness, has demonstrated that the DPP-4 inhibitor linagliptin reduces LV stiffness by decreasing cardiac fibrosis and cardiomyocyte Fpassive. This evidence concerns the gene DPP4 and metabolic syndrome.